Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Antoni, Delphine ^a   Natarajan Ame, Shanti ^b   Meyer, Philippe ^a   Niederst, Claudine ^a   Bourahla, Khalil ^a   Noel, Georges ^a  

^a Regional Paul Strauss Cancer Centre   (France)

^b HÔPITAL CIVIL   (France)

Author keywords

Dose distribution; Hodgkin's lymphoma; IMRT

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DOXORUBICIN; ETOPOSIDE; PREDNISONE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; BREAST; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; ESOPHAGUS; FOLLOW UP; HEART; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE DISTRIBUTION; SUPRADIAPHRAGMATIC HODGKIN DISEASE; SURVIVAL RATE; THREE DIMENSIONAL IMAGING; THYROID GLAND; TOMOTHERAPY; TREATMENT OUTCOME; CANCER STAGING; DISEASE FREE SURVIVAL; FEMALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROCEDURES; RADIATION DOSE; YOUNG ADULT;

ADOLESCENT; ADULT; DISEASE-FREE SURVIVAL; FEMALE; HODGKIN DISEASE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED; YOUNG ADULT;

EID: 84876834913     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-112     Document Type: Article

References (75)

1. Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004, 22(14):2835-2841. 10.1200/JCO.2004.12.170, 15199092.
2. Engert A, Franklin J, Eich HT, Brillant C, Sehlen S, Cartoni C, Herrmann R, Pfreundschuh M, Sieber M, Tesch H. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. J Clin Oncol 2007, 25(23):3495-3502. 10.1200/JCO.2006.07.0482, 17606976.
3. Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van't Veer MB, Walewski JA. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. N Engl J Med 2007, 357(19):1916-1927. 10.1056/NEJMoa064601, 17989384.
4. Noordijk EM, Carde P, Dupouy N, Hagenbeek A, Krol AD, Kluin-Nelemans JC, Tirelli U, Monconduit M, Thomas J, Eghbali H. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. J Clin Oncol 2006, 24(19):3128-3135. 10.1200/JCO.2005.05.2746, 16754934.
5. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, Friedman DL, Marina N, Hobbie W, Kadan-Lottick NS. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006, 355(15):1572-1582. 10.1056/NEJMsa060185, 17035650.
6. Meadows AT, Obringer AC, Marrero O, Oberlin O, Robison L, Fossati-Bellani F, Green D, Voute PA, Morris-Jones P, Greenberg M. Second malignant neoplasms following childhood Hodgkin's disease: treatment and splenectomy as risk factors. Med Pediatr Oncol 1989, 17(6):477-484.
7. Moser EC, Noordijk EM, van Leeuwen FE, le Cessie S, Baars JW, Thomas J, Carde P, Meerwaldt JH, van Glabbeke M, Kluin-Nelemans HC. Long-term risk of cardiovascular disease after treatment for aggressive non-Hodgkin lymphoma. Blood 2006, 107(7):2912-2919. 10.1182/blood-2005-08-3392, 16339404.
8. Weber DC, Johanson S, Peguret N, Cozzi L, Olsen DR. Predicted risk of radiation-induced cancers after involved field and involved node radiotherapy with or without intensity modulation for early-stage hodgkin lymphoma in female patients. Int J Radiat Oncol Biol Phys 2011, 81(2):490-497. 10.1016/j.ijrobp.2010.05.035, 20800383.
9. Kirova YM, Vilcoq JR, Asselain B, Sastre-Garau X, Fourquet A. Radiation-induced sarcomas after radiotherapy for breast carcinoma: a large-scale single-institution review. Cancer 2005, 104(4):856-863. 10.1002/cncr.21223, 15981282.
10. Bhatia S, Robison LL, Oberlin O, Greenberg M, Bunin G, Fossati-Bellani F, Meadows AT. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med 1996, 334(12):745-751. 10.1056/NEJM199603213341201, 8592547.
11. Swerdlow AJ, Barber JA, Hudson GV, Cunningham D, Gupta RK, Hancock BW, Horwich A, Lister TA, Linch DC. Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. J Clin Oncol 2000, 18(3):498-509.
12. Green DM, Hyland A, Barcos MP, Reynolds JA, Lee RJ, Hall BC, Zevon MA. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol 2000, 18(7):1492-1499.
13. Henderson TO, Whitton J, Stovall M, Mertens AC, Mitby P, Friedman D, Strong LC, Hammond S, Neglia JP, Meadows AT. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2007, 99(4):300-308. 10.1093/jnci/djk052, 17312307.
14. Mertens AC, Yasui Y, Neglia JP, Potter JD, Nesbit ME, Ruccione K, Smithson WA, Robison LL. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol 2001, 19(13):3163-3172.
15. Neglia JP, Friedman DL, Yasui Y, Mertens AC, Hammond S, Stovall M, Donaldson SS, Meadows AT, Robison LL. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst 2001, 93(8):618-629. 10.1093/jnci/93.8.618, 11309438.
16. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, Tarbell NJ, Stevenson MA, Friedberg JW, Mauch PM. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002, 100(6):1989-1996. 10.1182/blood-2002-02-0634, 12200357.
17. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ 1994, 309(6948):162-166. 10.1136/bmj.309.6948.162, 2540717, 8044095.
18. van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, Schaapveld M, van Heerde P, Burgers JM, Somers R. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000, 18(3):487-497.
19. Sankila R, Garwicz S, Olsen JH, Dollner H, Hertz H, Kreuger A, Langmark F, Lanning M, Moller T, Tulinius H. Risk of subsequent malignant neoplasms among 1,641 Hodgkin's disease patients diagnosed in childhood and adolescence: a population-based cohort study in the five Nordic countries. Association of the Nordic Cancer Registries and the Nordic Society of Pediatric Hematology and Oncology. J Clin Oncol 1996, 14(5):1442-1446.
20. Clemons M, Loijens L, Goss P. Breast cancer risk following irradiation for Hodgkin's disease. Cancer Treat Rev 2000, 26(4):291-302. 10.1053/ctrv.2000.0174, 10913384.
21. Bhatia S, Sather HN, Pabustan OB, Trigg ME, Gaynon PS, Robison LL. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood 2002, 99(12):4257-4264. 10.1182/blood.V99.12.4257, 12036851.
22. Girinsky T, Ghalibafian M. Radiotherapy of hodgkin lymphoma: indications, new fields, and techniques. Semin Radiat Oncol 2007, 17(3):206-222. 10.1016/j.semradonc.2007.02.007, 17591568.
23. Engert A, Plutschow A, Eich HT, Lohri A, Dorken B, Borchmann P, Berger B, Greil R, Willborn KC, Wilhelm M. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010, 363(7):640-652. 10.1056/NEJMoa1000067, 20818855.
24. Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T. Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2011, 80(1):199-205. 10.1016/j.ijrobp.2010.09.007, 21481723.
25. Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, Azoury F, al Hamokles H, Lefkopoulos D, Girinsky T. Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2012, 82(4):1522-1527. 10.1016/j.ijrobp.2011.05.015, 21705151.
26. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, Gaynor ER, Peterson BA, Miller TP, Fisher RI. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. J Clin Oncol 2001, 19(22):4238-4244.
27. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997, 111(6):1718-1723. 10.1378/chest.111.6.1718, 9187199.
28. Commowick O, Gregoire V, Malandain G. Atlas-based delineation of lymph node levels in head and neck computed tomography images. Radiother Oncol 2008, 87(2):281-289. 10.1016/j.radonc.2008.01.018, 18279984.
29. Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der Maazen R, Aleman B, Paumier A, Meijnders P, Lievens Y. The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 2008, 88(2):202-210. 10.1016/j.radonc.2008.05.012, 18555548.
30. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 2006, 79(3):270-277. 10.1016/j.radonc.2006.05.015, 16797755.
31. Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, Lumbroso J. Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting?. Radiother Oncol 2007, 85(2):178-186. 10.1016/j.radonc.2007.07.003, 17719110.
32. Prescribing, recording and reporting photon beam therapy 1993, Bethesda USA: ICRU Report 50.
33. Prescribing, recording and reporting photon beam therapy 1999, Bethesda USA: ICRU (supplement to ICRU report 50), report 62.
34. Prescribing, Recording, and Reporting Intensity-Modulated Photon-Beam Therapy (IMRT)(ICRU Report 83) ICRU Report 83, (Supplement to ICRU Report 50). J ICRU 2010, 10.
35. Feuvret L, Noel G, Mazeron JJ, Bey P. Conformity index: a review. Int J Radiat Oncol Biol Phys 2006, 64(2):333-342. 10.1016/j.ijrobp.2005.09.028, 16414369.
36. Graham MV, Purdy JA, Emami B, Harms W, Bosch W, Lockett MA, Perez CA. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 1999, 45(2):323-329. 10.1016/S0360-3016(99)00183-2, 10487552.
37. Marks LB. Dosimetric predictors of radiation-induced lung injury. Int J Radiat Oncol Biol Phys 2002, 54(2):313-316.
38. Marks LB, Bentzen SM, Deasy JO, Kong FM, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD. Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S70-76. 3576042, 20171521.
39. Marks LB, Yorke ED, Jackson A, Ten Haken RK, Constine LS, Eisbruch A, Bentzen SM, Nam J, Deasy JO. Use of normal tissue complication probability models in the clinic. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S10-19.
40. Seppenwoolde Y, Lebesque JV, de Jaeger K, Belderbos JS, Boersma LJ, Schilstra C, Henning GT, Hayman JA, Martel MK, Ten Haken RK. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 2003, 55(3):724-735. 10.1016/S0360-3016(02)03986-X, 12573760.
41. Vlachaki M, Castellon I, Leite C, Perkins T, Ahmad S. Impact of respiratory gating using 4-dimensional computed tomography on the dosimetry of tumor and normal tissues in patients with thoracic malignancies. Am J Clin Oncol 2009, 32(3):262-268. 10.1097/COC.0b013e318184b33a, 19433968.
42. Yahalom J, Mauch P. The involved field is back: issues in delineating the radiation field in Hodgkin's disease. Ann Oncol 2002, 13(Suppl 1):79-83. 10.1093/annonc/13.S1.79, 12078908.
43. Maraldo MV, Aznar MC, Vogelius IR, Petersen PM, Specht L. Involved node radiation therapy: an effective alternative in early-stage hodgkin lymphoma. Int J Radiat Oncol Biol Phys 2013, 85(4):1057-1065. 10.1016/j.ijrobp.2012.08.041, 23200817.
44. Eich HT, Muller RP, Engenhart-Cabillic R, Lukas P, Schmidberger H, Staar S, Willich N. Involved-node radiotherapy in early-stage Hodgkin's lymphoma. Definition and guidelines of the German Hodgkin Study Group (GHSG). Strahlenther Onkol 2008, 184(8):406-410. 10.1007/s00066-008-1882-7, 18956517.
45. Girinsky T, van der Maazen R, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E. Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2006, 79(3):270-277.
46. Ghalibafian M, Beaudre A, Girinsky T. Heart and coronary artery protection in patients with mediastinal Hodgkin lymphoma treated with intensity-modulated radiotherapy: dose constraints to virtual volumes or to organs at risk?. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology 2008, 87(1):82-88.
47. Chera BS, Rodriguez C, Morris CG, Louis D, Yeung D, Li Z, Mendenhall NP. Dosimetric comparison of three different involved nodal irradiation techniques for stage II Hodgkin's lymphoma patients: conventional radiotherapy, intensity-modulated radiotherapy, and three-dimensional proton radiotherapy. Int J Radiat Oncol Biol Phys 2009, 75(4):1173-1180. 10.1016/j.ijrobp.2008.12.048, 19386423.
48. Cella L, Liuzzi R, Magliulo M, Conson M, Camera L, Salvatore M, Pacelli R. Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. Radiat Oncol 2010, 5:33. 10.1186/1748-717X-5-33, 2881006, 20459790.
49. Tubiana M. Can we reduce the incidence of second primary malignancies occurring after radiotherapy? A critical review. Radiother Oncol 2009, 91(1):4-15. discussion 11-13, 10.1016/j.radonc.2008.12.016, 19201045.
50. Meyer RM, Gospodarowicz MK, Connors JM, Pearcey RG, Wells WA, Winter JN, Horning SJ, Dar AR, Shustik C, Stewart DA. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. N Engl J Med 2012, 366(5):399-408. 10.1056/NEJMoa1111961, 22149921.
51. Herbst C, Rehan FA, Skoetz N, Bohlius J, Brillant C, Schulz H, Monsef I, Specht L, Engert A. Chemotherapy alone versus chemotherapy plus radiotherapy for early stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011, 2. CD007110.
52. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011, 154(1):23-31. 10.1111/j.1365-2141.2011.08713.x, 21539537.
53. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, Stovall M, Robison LL, Hudson MM. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011, 117(6):1806-1816. 10.1182/blood-2010-04-278796, 3056636, 21037086.
54. Rademaker J, Schoder H, Ariaratnam NS, Strauss HW, Yahalom J, Steingart R, Oeffinger KC. Coronary artery disease after radiation therapy for Hodgkin's lymphoma: coronary CT angiography findings and calcium scores in nine asymptomatic patients. AJR Am J Roentgenol 2008, 191(1):32-37. 10.2214/AJR.07.3112, 18562721.
55. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson NO, Bennet AM, Fornander T, Gigante B, Jensen MB, Peto R. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011, 100(2):167-175. 10.1016/j.radonc.2011.06.016, 21752480.
56. Chung E, Corbett JR, Moran JM, Griffith KA, Marsh RB, Feng M, Jagsi R, Kessler ML, Ficaro EC, Pierce LJ. Is there a dose-response relationship for heart disease with low-dose radiation therapy?. Int J Radiat Oncol Biol Phys 2013, 85(4):959-964. 10.1016/j.ijrobp.2012.08.002, 23021709.
57. Constine LS, Tarbell N, Hudson MM, Schwartz C, Fisher SG, Muhs AG, Basu SK, Kun LE, Ng A, Mauch P. Subsequent malignancies in children treated for Hodgkin's disease: associations with gender and radiation dose. Int J Radiat Oncol Biol Phys 2008, 72(1):24-33. 10.1016/j.ijrobp.2008.04.067, 3531236, 18722263.
58. Alm El-Din MA, Hughes KS, Finkelstein DM, Betts KA, Yock TI, Tarbell NJ, Aisenberg AC, Taghian AG. Breast cancer after treatment of Hodgkin's lymphoma: risk factors that really matter. Int J Radiat Oncol Biol Phys 2009, 73(1):69-74. 10.1016/j.ijrobp.2008.03.066, 18538497.
59. Gervais-Fagnou DD, Girouard C, Laperriere N, Pintillie M, Goss PE. Breast cancer in women following supradiaphragmatic irradiation for Hodgkin's disease. Oncology 1999, 57(3):224-231. 10.1159/000012035, 10545791.
60. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993, 85(1):25-31. 10.1093/jnci/85.1.25, 8416252.
61. Tinger A, Wasserman TH, Klein EE, Miller EA, Roberts T, Piephoff JV, Kucik NA. The incidence of breast cancer following mantle field radiation therapy as a function of dose and technique. Int J Radiat Oncol Biol Phys 1997, 37(4):865-870. 10.1016/S0360-3016(97)00026-6, 9128963.
62. Travis LB. Evaluation of the risk of therapy-associated complications in survivors of Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2007, 1:192-196.
63. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003, 290(4):465-475. 10.1001/jama.290.4.465, 12876089.
64. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003, 95(13):971-980. 10.1093/jnci/95.13.971, 12837833.
65. Franklin J, Pluetschow A, Paus M, Specht L, Anselmo AP, Aviles A, Biti G, Bogatyreva T, Bonadonna G, Brillant C. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006, 17(12):1749-1760. 10.1093/annonc/mdl302, 16984979.
66. Swerdlow AJ, Schoemaker MJ, Allerton R, Horwich A, Barber JA, Cunningham D, Lister TA, Rohatiner AZ, Vaughan Hudson G, Williams MV. Lung cancer after Hodgkin's disease: a nested case-control study of the relation to treatment. J Clin Oncol 2001, 19(6):1610-1618.
67. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002, 94(3):182-192. 10.1093/jnci/94.3.182, 11830608.
68. Haberer S, Belin L, Le Scodan R, Kirova YM, Savignoni A, Stevens D, Moisson P, Decaudin D, Pierga JY, Reyal F. Locoregional treatment for breast carcinoma after Hodgkin's lymphoma: the breast conservation option. Int J Radiat Oncol Biol Phys 2012, 82(2):e145-152. 10.1016/j.ijrobp.2011.03.013, 21605948.
69. Renner R. Hormesis. Nietzsche's toxicology. Sci Am 2003, 289(3):28-30. 10.1038/scientificamerican0903-28, 14513515.
70. Epstein R, Hanham I, Dale R. Radiotherapy-induced second cancers: are we doing enough to protect young patients?. Eur J Cancer 1997, 33(4):526-530. 10.1016/S0959-8049(97)00056-7, 9274430.
71. Dorr W, Herrmann T. Second primary tumors after radiotherapy for malignancies. Treatment-related parameters. Strahlenther Onkol 2002, 178(7):357-362. 10.1007/s00066-002-0951-6, 12163989.
72. Karlsson P, Holmberg E, Johansson KA, Kindblom LG, Carstensen J, Wallgren A. Soft tissue sarcoma after treatment for breast cancer. Radiother Oncol 1996, 38(1):25-31. 10.1016/0167-8140(95)01663-5, 8850423.
73. Suit H, Goldberg S, Niemierko A, Ancukiewicz M, Hall E, Goitein M, Wong W, Paganetti H. Secondary carcinogenesis in patients treated with radiation: a review of data on radiation-induced cancers in human, non-human primate, canine and rodent subjects. Radiat Res 2007, 167(1):12-42. 10.1667/RR0527.1, 17214511.
74. Diallo I, Haddy N, Adjadj E, Samand A, Quiniou E, Chavaudra J, Alziar I, Perret N, Guerin S, Lefkopoulos D. Frequency distribution of second solid cancer locations in relation to the irradiated volume among 115 patients treated for childhood cancer. Int J Radiat Oncol Biol Phys 2009, 74(3):876-883. 10.1016/j.ijrobp.2009.01.040, 19386434.
75. Beneyton V, Niederst C, Vigneron C, Meyer P, Becmeur F, Marcellin L, Lutz P, Noel G. Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma. BMC Med Phys 2012, 12:2. 3598555, 22742393.